

Notice: This opinion is subject to formal revision before publication in the advance sheets of Southern Reporter. Readers are requested to notify the **Reporter of Decisions**, Alabama Appellate Courts, 300 Dexter Avenue, Montgomery, Alabama 36104-3741 ((334) 229-0649), of any typographical or other errors, in order that corrections may be made before the opinion is printed in Southern Reporter.

SUPREME COURT OF ALABAMA

OCTOBER TERM, 2008-2009

1071020

Mobile OB-GYN, P.C.

v.

Wendy Godwin Baggett

1071081

Wendy Godwin Baggett

v.

Mobile OB-GYN, P.C.

Appeals from Mobile Circuit Court
(CV-05-2615)

1071020, 1071081

STUART, Justice.

Wendy Godwin Baggett sued Mobile OB-GYN, P.C., in the Mobile Circuit Court alleging that one of its physicians, Dr. Phillip Madonia, committed medical malpractice while treating her during her pregnancy and that the death of her baby shortly after childbirth was the direct result of Dr. Madonia's malpractice. Following a trial, the jury returned a verdict in favor of Baggett and against Mobile OB-GYN in the amount of \$8 million. The trial court subsequently ordered a remittitur of \$3 million, reducing the damages award to \$5 million. Mobile OB-GYN now appeals the judgment entered against it, and Baggett has cross-appealed, challenging the remittitur. We reverse the judgment entered against Mobile OB-GYN and remand the cause for a new trial; accordingly, Baggett's cross-appeal is dismissed as moot.

I.

Baggett became a patient at Mobile OB-GYN on March 1, 2004, when Dr. Madonia began treating her for high blood pressure and depression. At that visit and at succeeding visits over the next several months, Dr. Madonia tried prescribing various medications to treat Baggett, eventually

1071020, 1071081

settling on Benicar for her high blood pressure and Wellbutrin and Prozac for her depression. Baggett testified that the medications Dr. Madonia prescribed had a positive impact on how she felt.

On October 25, 2004, Baggett again visited Mobile OB-GYN after a home pregnancy test indicated that she was pregnant. Dr. Madonia confirmed the results of that test, estimated that she was approximately six weeks pregnant based on a pelvic exam, and gave Baggett a prescription for prenatal vitamins. Dr. Madonia testified that he also spoke with Baggett about the medications she was taking and told her that she could continue taking Wellbutrin and Prozac but that she should stop taking Benicar because there were strong warnings against taking it during pregnancy. However, Baggett testified that Dr. Madonia told her that it was fine for her to continue taking all of her current medications, and she continued to do so.¹ Baggett testified that on several succeeding visits to Dr. Madonia's office she asked about the safety of the medications she was taking during a pregnancy, but neither Dr. Madonia nor his nurse, Amy Clossman, ever told her to stop

¹Baggett in fact refilled her prescription for Benicar on October 27, 2004, two days after her visit with Dr. Madonia.

1071020, 1071081

taking Benicar; both Dr. Madonia and Clossman testified that Baggett never asked them whether she should continue to take Benicar once she learned she was pregnant and that they did not know that she continued taking it during her pregnancy. Although Baggett's medical records indicate the date on which Benicar was prescribed to her, none of Dr. Madonia's notes and nothing in the medical records maintained by Mobile OB-GYN indicate that she was ever told to discontinue taking Benicar after she became pregnant.

Baggett returned to Mobile OB-GYN for monthly pregnancy checkups in November, December, and January. Ultrasound examinations were conducted in November and December, and those examinations, along with other testing done during those visits, indicated that Baggett's pregnancy was progressing normally. On February 7, 2005, Baggett returned to Mobile OB-GYN for her fifth prenatal visit with Dr. Madonia. Another ultrasound examination was performed on this visit, and the technician conducting this examination did not indicate any problems in her summary of the examination; in fact, she specifically noted that the level of amniotic fluid was normal. However, Dr. Madonia subsequently testified that

1071020, 1071081

Baggett's amniotic-fluid level at the time of that ultrasound examination, 6.69 centimeters, was low, but that he did not realize it at the time because he had relied upon the technician's summation of the ultrasound examination instead of looking at the entire report. Low amniotic fluid, or oligohydramnios, is a condition associated with Benicar exposure during pregnancy.

Baggett's next two prenatal visits to Mobile OB-GYN took place on March 7 and April 4, and nothing during those visits indicated that Baggett's pregnancy was anything other than normal.² On April 25, Baggett returned for her next scheduled appointment. During her visit with Dr. Madonia, Baggett reported that she had experienced some vaginal mucous discharge. Dr. Madonia examined her cervix, but did not see anything abnormal. To assure Baggett that everything was normal, however, Dr. Madonia ordered another ultrasound examination. When this ultrasound was performed, it showed that Baggett had virtually no amniotic fluid and that the fetus was in distress. Dr. Madonia immediately transferred Baggett to the high-risk obstetrics clinic at the University

²It appears that an ultrasound examination was not performed during either of those visits.

1071020, 1071081

of South Alabama Children's and Women's Hospital, and shortly thereafter an emergency caesarean section was performed and a baby boy was delivered.

The baby's condition, however, was not good, and, after an examination, his primary physician, Dr. Richard Whitehurst, indicated in his notes that the baby suffered from hypotension related to maternal Benicar exposure. In another note written the following day, after the baby was given a transfusion, Dr. Whitehurst stated his diagnosis as hypotension, anuria, and Benicar exposure. The baby died on April 27, approximately 36 hours after birth. Baggett testified at trial that, following the baby's death, Dr. Whitehurst recommended that an autopsy be performed because he believed that Benicar exposure was the cause of the baby's problems. An autopsy was performed, and the pathologist who performed that autopsy, Dr. Elizabeth Mancini-Gardner, concluded that "[t]he most likely cause of death in this case is decreased uteroplacental blood flow." Baggett introduced evidence at trial indicating that decreased uteroplacental blood flow in a mother, as well as hypotension and anuria in a baby, are conditions associated with exposure to Benicar during the pregnancy.

1071020, 1071081

On July 12, 2005, Baggett filed a medical-malpractice action against Mobile OB-GYN in the Mobile Circuit Court, alleging that its negligence and/or wantonness was responsible for the death of her baby. The case proceeded to trial on November 5, 2007, and, at the close of all the evidence, the trial court charged the jury on the following five counts of negligence:

"Now, Wendy Baggett brings this lawsuit alleging the following: Negligently prescrib[ed] the drug Benicar to Wendy Godwin Baggett; two, negligently failed to appropriately follow up with Wendy Baggett and monitor her condition and that of her child; three, negligently did not have in place appropriate procedures, safeguards, and protocols to prevent the drug Benicar from being prescribed to pregnant patients; four, negligently failed to appreciate the developing signs of the developing damage the drug Benicar was causing during the pregnancy and failed to institute any remedial measures; and five, negligently did not properly evaluate the risk of allowing a pregnant patient to remain on the drug Benicar."

On November 9, 2007, the jury returned a general verdict in favor of Baggett and against Mobile OB-GYN in the amount of \$8 million. Mobile OB-GYN subsequently moved for a judgment as a matter of law, a new trial, or a remittitur, and, following a hearing on Mobile OB-GYN's motion, the trial court entered an order denying the requests for a judgment as a matter of

1071020, 1071081

law and a new trial but ordering a remittitur and reducing the damages to \$5 million. On April 21, 2008, Mobile OB-GYN filed its notice of appeal to this Court, and, on May 1, 2008, Baggett filed her cross-appeal.

II.

"When reviewing a ruling on a motion for a JML [judgment as a matter of law], this Court uses the same standard the trial court used initially in deciding whether to grant or deny the motion for a JML. Palm Harbor Homes, Inc. v. Crawford, 689 So. 2d 3 (Ala. 1997). Regarding questions of fact, the ultimate question is whether the nonmovant has presented sufficient evidence to allow the case to be submitted to the jury for a factual resolution. Carter v. Henderson, 598 So. 2d 1350 (Ala. 1992). The nonmovant must have presented substantial evidence in order to withstand a motion for a JML. See § 12-21-12, Ala. Code 1975; West v. Founders Life Assurance Co. of Florida, 547 So. 2d 870, 871 (Ala. 1989). A reviewing court must determine whether the party who bears the burden of proof has produced substantial evidence creating a factual dispute requiring resolution by the jury. Carter, 598 So. 2d at 1353. In reviewing a ruling on a motion for a JML, this Court views the evidence in the light most favorable to the nonmovant and entertains such reasonable inferences as the jury would have been free to draw. Id. Regarding a question of law, however, this Court indulges no presumption of correctness as to the trial court's ruling. Ricwil, Inc. v. S.L. Pappas & Co., 599 So. 2d 1126 (Ala. 1992)."

Waddell & Reed, Inc. v. United Investors Life Ins. Co., 875 So. 2d 1143, 1152 (Ala. 2003). The plaintiff in a medical-

1071020, 1071081

malpractice action is required to present substantial evidence indicating both that the defendant health-care provider "failed to comply with the standard of care and that such failure probably caused the injury or death in question." § 6-5-549, Ala. Code 1975.

III.

Mobile OB-GYN argues that it is entitled to a new trial because, it claims, the trial court erred by submitting to the jury, in addition to a claim that was supported by substantial evidence, claims that were not supported by substantial evidence, that is, "evidence of such weight and quality that fair-minded persons in the exercise of impartial judgment can reasonably infer the existence of the fact sought to be proved." West v. Founders Life Assurance Co. of Florida, 547 So. 2d 870, 871 (Ala. 1989). Mobile OB-GYN argues that, of the five counts submitted to the jury in this case, only one was supported by substantial evidence and, citing Long v. Wade, 980 So. 2d 378, 385 (Ala. 2007), argues that the judgment entered on the jury's general verdict must therefore be reversed because both a good count and a bad count were

1071020, 1071081

submitted to the jury. In Long, this Court stated that, under the so-called good-count/bad-count rule,

"'when the trial court submits to the jury a "good count" -- one that is supported by the evidence -- and a "bad count" -- one that is not supported by the evidence -- and the jury returns a general verdict, this Court cannot presume that the verdict was returned on the good count. In such a case, a judgment entered upon the verdict must be reversed.'"

"Larrimore v. Dubose, 827 So. 2d 60, 63 (Ala. 2001) (quoting Alfa Mut. Ins. Co. v. Roush, 723 So. 2d 1250, 1257 (Ala. 1998)) (emphasis added)."

980 So. 2d at 385. Accordingly, if any of the counts submitted to the jury in this case were not supported by substantial evidence, Mobile OB-GYN is entitled to a judgment as a matter of law on those unsupported "bad counts," and the judgment entered on the jury's verdict is due to be reversed and the cause remanded for a new trial on the remaining "good counts." Mobile OB-GYN does not dispute that there is substantial evidence supporting the first count submitted to the jury, i.e., the count alleging that Dr. Madonia negligently prescribed Benicar to Baggett; however, it objects to all four other counts. We therefore review each of those

1071020, 1071081

four counts to determine whether they were supported by substantial evidence at trial.

The second count, alleging that Mobile OB-GYN "negligently failed to appropriately follow up with Wendy Baggett and monitor her condition and that of her child," and the fourth count, alleging that Mobile OB-GYN "negligently failed to appreciate the developing signs of the developing damage the drug Benicar was causing during the pregnancy and failed to institute any remedial measures," both relate to the ultrasound examination that was performed on February 7, 2005, and are therefore treated together. The second count specifically concerns Dr. Madonia's failure to recognize that Baggett's amniotic fluid was low, and the fourth count relates to his failure to take remedial measures to protect the fetus, including telling Baggett to cease taking Benicar, after the February 7 ultrasound examination revealed a low amniotic-fluid level.

At trial, Baggett presented substantial evidence indicating that, at the time the February 7, 2005, ultrasound was performed her amniotic-fluid level was low, that the applicable standard of care required Dr. Madonia to take

1071020, 1071081

action based on that fact, and that he failed to do so. That evidence included the following testimony from Dr. Madonia's videotaped deposition, which was shown at trial:

"Q. All right. Doctor, isn't the standard of care when you have a low amniotic fluid reading like this to hospitalize the mother to consider your treatment options?

"A. Depends on -- you know, we probably wouldn't hospitalize her with an amniotic fluid. We would repeat this at some point. Repeat it probably the next day.

"Q. But you didn't do that in this case; did you?

"A. No, I didn't.

"Q. Okay. In fact, until I showed you the actual ultrasound reading, which is Exhibit 1F, you didn't realize that this mother had such a low reading; did you?

"A. No sir.

"Q. Okay. Thank you, Doctor. Doctor, if you had seen that ultrasound reading in February, would you have quizzed Ms. Baggett about whether she was still on Benicar?

"A. It's possible. I'm not sure what I -- I would have done something. I'm not sure what I would have done.

"Q. The normal part of what you would have done at that point is re-covered her medications with her?

"A. Probably.

1071020, 1071081

"Q. All right. And if she had told you 'I am still on Benicar,' you would have told her on February 7th to stop taking it; wouldn't you?

"A. Yes."

Baggett's expert witness, Dr. Mark Turrentine, also testified on this issue:

"Q. Doctor, based on your education, training, background, the materials you have reviewed, the facts you have become familiar with, do you have an opinion to a reasonable degree of medical certainty as to whether [Mobile OB-GYN] deviated [from the standard of care] by not taking additional action after an ultrasound reading came back showing amniotic fluid level of 6.69, which Dr. Madonia himself has testified was low and required additional attention?

"A. Yes.

"Q. What is your opinion?

"A. That there should have been further evaluation following that ultrasound.

"Q. So your opinion is [Mobile OB-GYN] did deviate?

"A. Deviated from the standard of care, yes."

Although Mobile OB-GYN also produced some evidence indicating that Baggett's amniotic-fluid level on February 7, 2005, 6.69 centimeters, is not universally considered to be a low reading, the evidence submitted by Baggett was nevertheless sufficient to constitute substantial evidence that Dr. Madonia

1071020, 1071081

breached the applicable standard of care. Mobile OB-GYN does not dispute this point, but it argues that Baggett subsequently failed to put forth substantial evidence indicating that Dr. Madonia's error caused the death of Baggett's baby, that is, that the baby probably would have lived if Dr. Madonia had recognized that Baggett's amniotic-fluid level was low and had taken remedial measures. See, e.g., § 6-5-549, Ala. Code 1975; DCH Healthcare Auth. v. Duckworth, 883 So. 2d 1214, 1217 (Ala. 2003) ("There must be more than the mere possibility that the negligence complained of caused the injury; rather there must be evidence that the negligence complained of probably caused the injury." (quoting Parker v. Collins, 605 So. 2d 824, 826 (Ala. 1992))).³

Initially, Mobile OB-GYN notes that when Baggett's expert, Dr. Turrentine, was asked specifically about causation, he was interrupted by an objection and, after that objection was resolved, failed to answer the question:

³In her brief to this Court, Baggett emphasizes that "[Mobile OB-GYN] did not offer a single witness who testified that baby Andrew could not be salvaged as of February 7." Baggett's brief, p. 17. However, this argument fails to recognize that the burden was on Baggett to prove causation, not on Mobile OB-GYN to disprove it.

1071020, 1071081

"Q. Now, assuming that on February 7th the doctors at Mobile OB-GYN had asked Wendy Baggett are you -- what medications you are taking, and she had told them Benicar, if the Benicar had been discontinued then, do you have an opinion as to whether little baby Andrew could have been salvaged, --

"[Mobile OB-GYN's attorney:] Your Honor, --

"Q. -- could have been saved?

"[Mobile OB-GYN's attorney:] -- pardon me. I object. Again, he has no qualifications to give that testimony at all."

Dr. Turrentine did not thereafter express an opinion as to whether the baby could have been saved had Benicar been discontinued on February 7; instead, he began discussing a medical-journal article. Dr. Turrentine summarized that article, Fetal Toxic Effects of Angiotensin II Receptor Antagonists: Case Report and Follow-Up after Birth, published in the January 2005 edition of The Annals of Pharmacotherapy, as follows:

"Q. And what is that particular article about?

"A. This article is -- has two components. It is described as a case report of an infant who was exposed to one of these ARB medications^[4] during

⁴Benicar belongs to a class of drugs alternately referred to at trial as angiotensin receptor blockers, or "ARB medications," and as angiotensin II receptor antagonists, or "AT1 antagonists."

1071020, 1071081

pregnancy. And then, in addition, it summarizes the articles available up until that time of other case reports of infants that have been exposed to the ARB medication during pregnancy."

Dr. Turrentine also was asked what conclusions were drawn in this article:

"Q. Doctor, what conclusions were reached in this article about the survivability by an infant who had been on a medication such as Benicar and was then taken off of the medication Benicar up to the 28th week of pregnancy, bearing in mind that little Andrew's ultrasound was when he was approximately 22 weeks gestational age?

"A. The article here by [Marie-Andrée] Bos-Thompson, there are three -- of the ten reports that are there, there are three of them, and, again, they were -- these were ARB-like medications. They were -- none of them were specifically Benicar. They all act very similarly.

"In three of the cases where the medications were discontinued, I think one was at 24 weeks, one was at 25 weeks, and one at 28 weeks. And at the time the medications were discontinued, there was very minimal amniotic fluid around the baby. And in those three cases, within between two to six weeks, the fluid level came back to a sufficient level.

"Now one of these cases the family opted to end the pregnancy at 32 weeks. The other case had -- the baby died at 33 weeks. But in the third case the baby was live-born.

1071020, 1071081

"Q. And the baby that was live-born, two years after it was born, how was it doing?

"A. From this case report, actually it had regained a lot of its renal function and had improved tremendously."

Thus, at no point in his testimony or discussion of the medical-journal article did Dr. Turrentine ever state, as his expert opinion, that Baggett's baby probably would have survived if remedial action had been taken on February 7.⁵

However, even though Dr. Turrentine did not give an opinion on this point, Baggett argues that there is nevertheless substantial evidence in the record indicating that the baby would have survived if Mobile OB-GYN had taken remedial action on February 7. Baggett first argues that the

⁵In its brief to this Court, Mobile OB-GYN also emphasizes that of the three cases discussed by Dr. Turrentine in summarizing the medical-journal article, only one baby survived:

"The fact that one baby survived out of three reported cases proves nothing. These three cases are not shown to present a sufficient statistical sample having any application to other babies exposed to Benicar. In fact, if they suggest anything at all, it is that the Baggett baby was likely to die even if Mrs. Baggett had stopped taking Benicar following the February 7 ultrasound."

Mobile OB-GYN's brief, p. 37.

1071020, 1071081

article discussed by Dr. Turrentine is itself an expert source establishing causation. However, an examination of that article reveals that it does not, in fact, support that proposition. Indeed, after summarizing 15 cases in which fetuses were exposed to ARB medications similar to Benicar, which medications are referred to in the article as "AT1 antagonists," the article states that "[b]ased on these 15 case reports, it is not possible to conclude that the risk is really reduced when treatment is stopped early in pregnancy. Rather, it does support avoidance of AT1 antagonists throughout pregnancy." Marie-Andrée Bos-Thompson et al., Fetal Toxic Effects of Angiotensin II Receptor Antagonists: Case Report and Follow-Up after Birth, 39 The Annals of Pharmacotherapy 157, 160 (January 2005). The article concludes as follows:

"Our case and review of other reported cases support the recommendation to avoid AT1 antagonists during pregnancy. AT1 antagonists are responsible for severe oligoamnios, which can lead to neonatal renal insufficiency and other associated abnormalities. If a pregnant woman is accidentally prescribed an AT1 antagonist, the agent should be stopped as soon as possible. Monitoring of amniotic fluid volume and β_2 -microglobulin fetal blood levels can be used to increase the likelihood of positive fetal outcomes."

1071020, 1071081

Id. Thus, this article at best stands for the proposition that if it is discovered that a pregnant woman is taking an AT1 antagonist such as Benicar, she should cease doing so as soon as possible, and steps can then be taken to increase the possibility of a positive outcome. However, at no point in the article is it stated, or even implied, that if those steps are taken there is a probability of a positive outcome to the pregnancy. This same problem also exists for Baggett in regard to the following testimony given by Dr. Madonia, which she also cites as evidence of causation:

"Q. According to this article at least, there are things you can attempt to do to reverse the effect of drugs such as Benicar; correct?

"A. Yes."

However, one cannot reasonably infer from this testimony that merely because a physician can attempt to reverse the effects of Benicar on a fetus, the probable result of such an attempt is a positive outcome to the pregnancy.

Baggett also cites the testimony of Mobile OB-GYN's two expert witnesses as further evidence of causation. Dr. Dwight Rouse and Dr. Max Rogers both testified on behalf of Mobile OB-GYN, and their expert opinion was that Baggett's amniotic-

1071020, 1071081

fluid level on February 7 was not low. They testified that her fluid level was normal because it was above the five-centimeter mark, which, they claimed, is the generally recognized cutoff point for oligohydramnios. Dr. Rouse specifically testified that "there was no indication, based on the impression of the experienced sonographer, that there was anything wrong on this ultrasound," and Dr. Rogers agreed that Baggett's amniotic-fluid level on February 7 was "normal"; both witnesses stated that no further action was required by Dr. Madonia based on the February 7 ultrasound. Baggett argues that these two witnesses were, in effect, declaring that the baby was "perfectly normal" on February 7 and would therefore have been fine had Baggett ceased taking Benicar as of that date.

However, Baggett's argument mischaracterizes Dr. Rouse's and Dr. Rogers's testimony. Neither witness ever expressed an opinion as to the health of Baggett's baby on February 7; rather, they expressed their opinions regarding the ultrasound report, specifically as it related to Baggett's amniotic-fluid level. Neither Dr. Rouse's statement that "there was no indication ... that there was anything wrong on this

1071020, 1071081

ultrasound" nor Dr. Rogers's testimony that the amniotic-fluid level was "normal" necessarily leads to the conclusion that the baby was "perfectly normal" on February 7.⁶

It was undisputed at trial that the use of AT1 antagonists such as Benicar during the second and third trimesters of pregnancy can cause injury or death to the fetus. It was also undisputed that Baggett was already approximately halfway through her second trimester when the February 7 ultrasound was conducted. No expert testified that Baggett's baby probably would have been saved if Baggett had stopped taking Benicar on February 7 and, even when looking at the entirety of the evidence in the light most favorable to Baggett, as we must, Waddell & Reed, Inc., 875 So. 2d at 1152, it is impossible to conclude that a fair-minded person in the exercise of impartial judgment could reasonably infer that Baggett's baby probably would have been saved if Baggett had stopped taking Benicar on February 7. At most, the evidence

⁶The evidence in the record that does speak to this point -- the package insert included with Benicar -- would actually seem to rebut Baggett's argument. That insert states that "[p]atients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury," thus indicating that Benicar may have already caused irreversible injuries even if the amniotic-fluid level appears normal.

1071020, 1071081

indicated only that the baby possibly could have been saved if Baggett had stopped taking Benicar on February 7. A mere possibility is an insufficient basis upon which to support a jury verdict in a medical-malpractice action. See § 6-5-549, Ala. Code 1975. Accordingly, the second and fourth counts are bad counts that should not have been submitted to the jury.⁷

IV.

⁷The Chief Justice's special writing, quoting from the autopsy report describing an autopsy that occurred 11 weeks after the February 7, 2005, ultrasound, states: "'[T]he most likely cause of death in this case is decreased uteroplacental blood flow, which appears to have been relatively recent in onset because the fetal ... weights' were within normal ranges for a 33-week-old fetus." ___ So. 3d at ___ (Cobb, C.J., concurring in part and dissenting in part). The Chief Justice's special writing, relying heavily on the evidence as to decreased blood flow being "relatively recent" concludes: "[T]here was substantial evidence that Benicar lowered Baggett's blood pressure and decreased blood flow to the uterus after the February 7 ultrasound, thereby probably and proximately causing the decrease in amniotic-fluid levels after the February 7 ultrasound, which in turn caused developmental defects in the fetus and, as a result, the death of the child." ___ So. 3d at ___. Of course, the doctor who prepared the autopsy report was not qualified as an expert on the effects of Benicar and offered no opinion on the role of Benicar in causation. Furthermore, as noted in this main opinion, no expert opinion testimony supports the view that events preceding the February 7 ultrasound examination can be disregarded so as to warrant the conclusion that lack of further evaluation by Dr. Madonia following the February 7 ultrasound probably caused the baby's death. Consequently, a jury verdict reaching the conclusion drawn in the Chief Justice's special writing would be based on speculation as to matters well beyond the expertise of a layperson.

1071020, 1071081

Mobile OB-GYN also argues that both the third count submitted to the jury -- that it breached the standard of care because it "negligently did not have in place appropriate procedures, safeguards, and protocols to prevent the drug Benicar from being prescribed to pregnant patients" -- and the fifth count submitted to the jury -- that it breached the standard of care because it "negligently did not properly evaluate the risk of allowing a pregnant patient to remain on the drug Benicar" -- are not supported by the evidence. Specifically, Mobile OB-GYN argues that there was no expert testimony establishing the standard of care applicable as to either count, establishing that there was a breach of that standard, or establishing that that alleged breach was the proximate cause of the baby's death. For the reasons that follow, we disagree.

In regard to the third count, Baggett's expert witness, Dr. Turrentine, gave the following testimony establishing the standard of care health-care providers should use in charting patients' medications and concluding that Mobile OB-GYN did not meet that standard:

"Q. Doctor, based on your education, training and background, is it the standard of care that the

1071020, 1071081

documenting of the continuance, discontinuance, prescription of medications is to be charted?

"A. The standard of care is that medications, when they are started and stopped, should be documented.

". . . .

"Q. Doctor, based on your education, training, background, the materials you reviewed, the facts you have become familiar with in this case, do you have an opinion to a reasonable degree of medical certainty as to whether [Mobile OB-GYN] violated the standard of care by not charting medications appropriately in their charts?

"A. Yes, they did not chart discontinuing the Benicar."

Dr. Rouse and Dr. Rogers subsequently testified that Dr. Madonia's charting practices did not breach the standard of care; however, Dr. Turrentine's testimony nevertheless constitutes substantial evidence that the standard of care required Dr. Madonia to chart when medications are started and stopped and that he breached the standard of care by failing to do so.

In regard to the fifth count, the unanimous testimony of every expert who testified at trial was that when a patient taking Benicar becomes pregnant, Benicar should be immediately discontinued. Indeed, the testimony of those experts

1071020, 1071081

indicated that it was a violation of the standard of care not to discontinue the use of Benicar. This testimony is tantamount to stating that a proper evaluation of the risks associated with leaving a pregnant patient on Benicar will always lead the evaluating physician to conclude that the risks are unacceptable and that Benicar should therefore be discontinued; by extension, any evaluation (or the failure to conduct an evaluation) that results in the patient being left on Benicar has necessarily been negligent and the evaluating physician who does not discontinue Benicar has breached the standard of care.

Thus, there was expert testimony establishing the standards of care applicable to the third and fifth counts as well as evidence indicating that Mobile OB-GYN failed to meet those standards. However, there still must be some evidence from which a jury could reasonably conclude that Mobile OB-GYN's breach of those standards proximately caused the death of Baggett's baby before those counts may be considered good counts. Mobile OB-GYN emphasizes that there was no expert testimony establishing proximate causation; however, the general facts underlying these counts, along with the

1071020, 1071081

undisputed expert testimony establishing that women who become pregnant should immediately discontinue the use of Benicar, constitute substantial evidence of proximate causation. If Mobile OB-GYN had maintained its patients' medical records in a manner consistent with the standard of care as established by Dr. Turrentine, Dr. Madonia would have had a record indicating that Baggett had been prescribed Benicar, and, upon reviewing that record, he would have also seen that the record indicated that Baggett had never stopped taking Benicar. The undisputed evidence indicates that Dr. Madonia knew that Benicar should not be taken by pregnant women; thus, his evaluation of the situation after reviewing her medical records and learning these facts would have necessarily resulted in his instructing Baggett to immediately cease taking Benicar. A jury could therefore reasonably conclude that Mobile OB-GYN's failure to properly chart Baggett's Benicar use led to the negligent failure to evaluate that resulted in her continued use of Benicar and the ultimate death of her baby. The third and fifth counts were accordingly good counts that were properly submitted to the jury.

1071020, 1071081

V.

After all the evidence was presented, the jury in this case was given a charge alleging five counts of negligence. It subsequently returned a general verdict in favor of Baggett and against Mobile OB-GYN, and the trial court entered a judgment based on that verdict. However, because two of the five counts the jury was charged on were not supported by substantial evidence, Mobile OB-GYN was entitled to a judgment as a matter of law on those two counts, and those counts should not have been submitted to the jury. Because we cannot presume that the jury's verdict was based on the three remaining good counts, we must therefore reverse the judgment entered on that verdict. Long, 980 So. 2d at 385. All other issues raised by Mobile OB-GYN in its appeal and the issue regarding the remittitur raised by Baggett in her cross-appeal are therefore moot, and the cause is remanded to the trial court for a new trial on the remaining good counts.

1071020 -- REVERSED AND REMANDED.

Lyons, Woodall, Smith, Bolin, Parker, and Shaw, JJ., concur.

Cobb, C.J., concurs in part and dissents in part.

Murdock, J., concurs in the result in part and dissents in part.

1071020, 1071081

1071081 -- DISMISSED.

Lyons, Woodall, Smith, Bolin, Parker, Murdock, and Shaw,
JJ., concur.

Cobb, C.J., dissents.

1071020, 1071081

COBB, Chief Justice (concurring in part and dissenting in part in case no. 1071020).

I concur with the majority's conclusion that the first, third, and fifth negligence counts were properly submitted to the jury. As to the majority's conclusion that the trial court erred in submitting the second and fourth negligence counts to the jury, I respectfully dissent.

The journal article referenced in the majority opinion and discussed in the record does not support Wendy Baggett's contention that the effects of Benicar can be reversed if the mother stops taking the drug. However, the record contains other evidence from which a jury could reasonably conclude that Bagget's exposure to Benicar after the February 7, 2005, ultrasound probably and proximately caused the death of the infant. See, e.g., Ala. Code 1975, § 6-5-549 ("In the case of a jury trial, the jury shall be instructed that in order to return a verdict against a health care provider, the jury shall be reasonably satisfied by substantial evidence that the health care provider failed to comply with the standard of care and that such failure probably caused the injury or death in question."); cf. Crutcher v. Williams, [Ms. 1050893, January 9, 2009], ___ So. 3d __, ___ (Ala. 2008) (opinion on

1071020, 1071081

return to second remand) ("[T]o prevail on a medical-malpractice claim ... the plaintiff must prove that a breach of the standard of care ... proximately and probably caused actual injury to the plaintiff."); Giles v. Brookwood Health Servs., Inc., 5 So. 3d 533 (Ala. 2008) (upholding a summary judgment for the defendant in a medical-malpractice case because the plaintiff did not present substantial evidence that the defendant physician's negligence proximately and probably caused injury to the plaintiff).

Mobile OB-GYN's own evidence at trial demonstrated that Benicar works by lowering the patient's blood pressure, and that in doing so it decreases the flow of blood to the uterus and, ultimately, to the fetus. Insufficient blood flow to the uterus is known as uteroplacental insufficiency. Baggett introduced evidence indicating that Benicar lowered her blood pressure and caused the blood flow to the uterus to decrease. The evidence, including Mobile OB-GYN's own evidence, also demonstrated that the decreased flow of blood to the uterus caused a decrease in the amount of amniotic fluid and that the decrease in the amount of amniotic fluid, in turn, caused the baby in this case to develop abnormally and ultimately to die.

1071020, 1071081

Substantial evidence also exists to show that the critical decrease in the level of amniotic fluid, caused by taking a medication one of the effects of which is to decrease blood flow to the uterus, occurred after the February 7, 2005, ultrasound. As the majority notes, according to Mobile OB-GYN's expert witnesses, the amniotic-fluid level at the time of the February 7 ultrasound was within the normal range. However, the undisputed evidence showed that, at the time of the child's birth almost 11 weeks (almost the length of a trimester) later, Baggett had virtually no amniotic fluid. Moreover, Dr. Elizabeth Mancini-Gardner, who performed the autopsy, concluded that "[t]he most likely cause of death in this case is decreased uteroplacental blood flow, which appears to have been relatively recent in onset because the fetal ... weights" were within normal ranges for a 33-week-old fetus.

Thus, although there was no proof at trial that ceasing the administration of Benicar can reverse damage that has already been done, there was substantial evidence that Benicar lowered Baggett's blood pressure and decreased the blood flow to the uterus after the February 7 ultrasound, thereby probably and proximately causing the decrease in amniotic-

1071020, 1071081

fluid levels after the February 7 ultrasound, which in turn caused developmental defects in the fetus and, as a result, the death of the child.

The majority states that "no expert opinion testimony supports the view that events preceding the February 7 ultrasound examination can be disregarded so as to warrant the conclusion that lack of further evaluation by Dr. Madonia following the February 7 ultrasound probably caused the baby's death." ___ So. 3d at ___ n.7. On this record, one could nevertheless reasonably conclude that the Benicar taken after the February 7 ultrasound probably cannot be disregarded as a proximate cause of the baby's death. The second and fourth counts were supported by sufficient evidence of proximate and probable causation and were properly submitted to the jury.

As a final note, I remain convinced of the correctness of Justice Murdock's special writing concurring in the result in Long v. Wade, 980 So. 2d 378, 387 (Ala. 2007), in which I concurred. It is clear from the record that both counsel and the trial judge attempted to adhere to Long, which had just been released at the time of the trial in this case. However, I note that this case illustrates the complications that can arise under Long when a jury renders a general verdict after

1071020, 1071081

considering allegations that the defendant committed several tortious acts or omissions, any one of which could form an independent basis for holding the defendant liable. See Long, 980 So. 2d at 386-87 ("[The plaintiff] may not, merely by including all alleged bases of recovery in a single count of their complaint, avoid the good-count/bad-count rule [The plaintiff's claims] are not merely different theories on which to recover for the same acts or omissions, but constitute entirely separate acts or omissions, which form discrete and independent bases for potential recovery. ... Upon sufficient proof, each one carries the potential for liability."). In light of Long, the pleading requirements of § 6-5-551, Ala. Code 1975, a part of the Alabama Medical Liability Act, and the majority's holding today, it appears that special verdicts or general verdicts accompanied by interrogatories may be a necessity in many medical-malpractice cases. See Rule 49(b) and (c), Ala. R. Civ. P. (regarding special verdicts and general verdicts accompanied by answers to interrogatories).

1071020, 1071081

MURDOCK, Justice (concurring in the result in part and dissenting in part in case no. 1071020).

With respect to the appeal in case no. 1071020, I concur in the result reached by the main opinion except as to the fifth count of Wendy Baggett's complaint, as to which I respectfully dissent. I write separately to address the third and fifth counts of the complaint.

The Third Count

In the first trial of this case, the third count of Baggett's complaint alleged that Mobile OB-GYN had breached the standard of care because it "negligently did not have in place appropriate procedures, safeguards, and protocols to prevent the drug Benicar from being prescribed to pregnant patients." Baggett adduced evidence during trial that, if believed by the jury, indicated that Dr. Madonia's nurse did not know what Benicar was before Baggett's baby was delivered; that the staff of Mobile OB-GYN did not ask patients, during every prenatal visit, what medications they were taking; that some Mobile OB-GYN staff erroneously believed that Dr. Madonia automatically discontinued all medications when a patient became pregnant; and that Dr. Madonia did not indicate on Baggett's medical chart that he had allegedly discontinued

1071020, 1071081

Benicar. Further, although disputed, there was evidence from which the jury reasonably could find that Dr. Madonia himself did not ask Baggett on prenatal visits what medications she was taking and, as discussed in the main opinion, that neither Dr. Madonia nor his staff followed charting practices that would reveal this information.⁸

The extreme nature of the risk to pregnant patients of taking Benicar was not only testified to by experts, it was undisputed. Accordingly, if proven, the fact that Mobile OB-GYN did not have in place necessary procedures or practices for learning whether a pregnant patient was taking a drug as dangerous to a fetus as Benicar -- and especially an appropriate procedure or practice to determine or reveal whether a pregnant patient was still taking a drug recently prescribed by Dr. Madonia himself that would be dangerous to a developing fetus -- would entail a "'lack of care [that] is so apparent ... as to be understood by a layman, and [to]

⁸Consistent with expert testimony introduced by Baggett at trial, not to mention its ability to use its own common sense and experience, the jury could have found that such charting practices would include a practice of always charting both the prescription of and the discontinuation of drugs that posed a danger to pregnant women and a practice of checking for both types of entries with respect to patients who become pregnant.

1071020, 1071081

require[] only common knowledge and experience to understand it.'" Ex parte HealthSouth Corp., 851 So. 2d 33, 39 (Ala. 2002) (quoting Tuscaloosa Orthopedic Appliance Co. v. Wyatt, 460 So. 2d 156, 161 (Ala. 1984), quoting in turn Dimoff v. Maitre, 432 So. 2d 1225, 1226-27 (Ala. 1983)). Likewise, as to the issue of causation, it is well within the ken of a layperson to be able to infer how appropriate charting practices would have made it apparent in a timely manner that Baggett remained on Benicar after she became pregnant.

The Fifth Count

I disagree, however, with the main opinion's treatment of count five of the complaint. Baggett alleges in count five that Dr. Madonia "negligently did not properly evaluate the risk of allowing a pregnant patient to remain on the drug Benicar." The record, however, at least as it developed at the first trial of this case, did not support such an allegation. In point of fact, there was no dispute at the first trial but that Dr. Madonia actually did know and did appreciate, at the time he was treating Baggett, the risk Benicar posed to fetuses. The dispute was not whether Dr. Madonia had this knowledge, but rather whether he acted upon it -- either by implementing appropriate procedures to

1071020, 1071081

prevent patients like Baggett from remaining on such a drug or by actually informing Baggett that she should stop taking the drug. These are the issues to which the evidence at the first trial was directed -- and these issues are subsumed by the first and third counts of the complaint. Accordingly, the charging of the jury as to the fifth count in the first trial of this case was at best potentially duplicative and confusing, see, e.g., American Cast Iron Pipe Co. v. Williams, 591 So. 2d 854, 856 (Ala. 1991), and 75A Am. Jur. 2d Trial § 991 (2007), and was at worst the charging of a "bad count."